Abstract
Purpose. GL331 is a new homolog of VP-16, and has demonstrated more efficacious anti-cancer activity in both the in vitro and in vivo lymphoma systems. To extensively explore GL331's clinical value, we furthermore evaluate the cytotoxicity and apoptosis-inducing activity of GL331 in several human cell lines from cancers that are not normally treated with VP-16.
Methods. By MTT and clonogenic survival assays, the cytotoxicities of GL331 and VP-16 were evaluated in a variety of cell lines including nasopharyngeal, hepatocellular, gastric, colon, cervical, and neuro-blastoma cancer types. Western blot analysis was performed to detect the MDR-1 level in these cell lines. By Annexin V-staining flow cytometry and detection of DNA ladders, the apoptosis-inducing activities of GL331 and VP-16 were also evaluated.
Results. GL331 showed more efficacy than its congener VP-16 in killing cancer cells. The estimated ID50 of GL331 were 2.5 to 17-fold lower than those of VP-16. GL331 possessed more cell-killing activity even in MDR-1-overexpressing cell lines such as HCC36 and SW620. Its higher cytotoxicity could be attributed by the elevated ability to induce apoptotic cell death.
Conclusions. GL331's overriding drug resistance and higher cancer cell-killing activity suggest its superiority in clinical cancer therapy.
Similar content being viewed by others
REFERENCES
J. Whang-Peng and T.-S. Huang. New trials of GL331, a novel topoisomerase II inhibitor, in treatment of solid tumors. J. Intern. Med. Taiwan 8:6–11 (1997).
T.-S. Huang, C.-H. Shu, Y.-L. Shih, H.-C. Huang, Y.-C. Su, Y. Chao, W. K. Yang, and J. Whang-Peng. Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Cancer Lett. 110:77–85 (1996).
M.-L. Kuo, S.-C. Shen, C.-H. Yang, S.-E. Chuang, A.-L. Cheng, and T.-S. Huang. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity. Oncogene 17:2225–2234 (1998).
T.-S. Huang, W. K. Yang, and J. Whang-Peng. GL331-induced disruption of cyclin B1/CDC 2 complex and inhibition of CDC 2 kinase activity. Apoptosis 1:213–217 (1996).
T.-S. Huang, C.-H. Shu, W. K. Yang, and J. Whang-Peng. Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis. Cancer Res. 57:2974–2978 (1997).
R. B. Lock and W. E. Ross. DNA topoisomerases in cancer therapy. Anticancer Drug Design 2:151–164 (1987).
L. F. Liu. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:351–375 (1989).
D. M. Sullivan, K.-C. Chow, and W. E. Ross. Topoisomerase II mediated mechanisms of drug resistance. In: D. Kessel (ed.), Resistance to antineoplastic drugs, pp. 281–292. FL: CRC Press, 1989.
C.-T. Lin, W.-Y. Chan, W. Chen, H.-M. Huang, H.-C. Wu, M.-M. Hsu, S.-M. Chuang, and C.-C. Wang. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab. Invest. 68:716–27 (1993).
C.-W. Wu, Y.-F. Chang, T.-H. Yeh, T.-J. Chang, W.-Y. Lui, F.-K. P'Eng, and C.-W. Chi. Steroid hormone receptors in three human gastric cancer cell lines. Digest. Dis. Sci. 39:2689–94 (1994).
R.-Y. Shyu, S.-Y. Jiang, C.-C. Wang, M.-F. Wu, H.-J. Harn, T.-M. Chang, and M.-Y. Yeh. Establishment and characterization of TSGH9201, a human gastric carcinoma cell line that is growth inhibited by epidermal growth factor. J. Surg. Oncol. 58:17–24 (1995).
R. Overbeeke, H. Steffens-Nakken, I. Vermes, C. Reuteling-sperger, and C. Haanen. Early features of apoptosis detected by four different flow cytometry assays. Apoptosis 3:115–121 (1998).
C.-H. Shu, W. K. Yang, and T.-S. Huang. Increased cyclin B1/CDC 2 kinase activity and phosphorylation of Bcl-2 associated with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. Apoptosis 1:141–146 (1996).
Z.-Q. Wang, Y.-H. Kuo, D. Schnur, P. Bowen, S.-Y. Liu, F.-S. Han, J.-Y. Chang, Y.-C. Cheng, and K.-H. Lee. Antitumor agents. 113. New 4β-arylamino derivatives of 4′-O-demethylepi-podophyllotoxic and related compounds as potent inhibitors of human DNA topoisomerase II. J. Med. Chem. 33:2660–2665 (1990).
J.-Y. Chang, F.-S. Han, S.-Y. Liu, Z.-Q. Wang, K.-H. Lee, and Y.-C. Cheng. Effect of 4β-arylamino derivatives of 4′-O-demethy-epipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants. Cancer Res. 51:1755–1759 (1991).
S. E. Bates, S. J. Currier, M. Alvarez, and A. T. Fojo. Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry 31:6366–6372 (1992).
D. T. Aftab, J. M. Yang, and W. N. Hait. Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug-resistant MCF-7 cells. Oncol. Res. 6:59–70 (1994).
W. P. Lee. P-glycoprotein is hyperphosphorylated in multidrug resistant HOB1 lymphoma cells treated with overdose of vincristine. Biochim. Biophys. Acta 1245:57–61 (1995).
S. Mishra and A. W. Hamburger. O-phospho-L-tyrosine inhibits cellular growth by activating protein tyrosine phosphatases. Cancer Res. 53:557–563 (1993).
A. Fandi, M. Altun, N. Azli, T. P. Armand, and E. Cvitkoric. Nasopharyngeal cancer, epidemiology, staging and treatment. Semin. Oncol. 21:382–388 (1994).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, TS., Lee, CC., Chao, Y. et al. A Novel Podophyllotoxin-Derived Compound GL331 Is More Potent than Its Congener VP-16 in Killing Refractory Cancer Cells. Pharm Res 16, 997–1002 (1999). https://doi.org/10.1023/A:1018971313256
Issue Date:
DOI: https://doi.org/10.1023/A:1018971313256